| __timestamp | Takeda Pharmaceutical Company Limited | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 7461000 |
| Thursday, January 1, 2015 | 650773000000 | 11960000 |
| Friday, January 1, 2016 | 619061000000 | 13108000 |
| Sunday, January 1, 2017 | 628106000000 | 17501000 |
| Monday, January 1, 2018 | 717599000000 | 22472000 |
| Tuesday, January 1, 2019 | 964737000000 | 24286000 |
| Wednesday, January 1, 2020 | 875663000000 | 29689000 |
| Friday, January 1, 2021 | 886361000000 | 38837000 |
| Saturday, January 1, 2022 | 997309000000 | 47489000 |
| Sunday, January 1, 2023 | 1053819000000 | 53379000 |
| Monday, January 1, 2024 | 1053819000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Takeda Pharmaceutical Company Limited and Xencor, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Takeda's SG&A expenses have surged by approximately 72%, reaching over a trillion yen by 2023. In contrast, Xencor's expenses have grown by about 615%, yet they remain a fraction of Takeda's, peaking at just over 53 million yen in 2023.
This stark difference highlights Takeda's expansive operations compared to Xencor's more focused approach. While Takeda's scale allows for significant market reach, Xencor's leaner structure may offer agility and cost efficiency. As the industry evolves, these strategies will continue to shape their financial landscapes. Missing data for 2024 suggests ongoing developments, making this a dynamic area to watch.
Sanofi and Xencor, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Dr. Reddy's Laboratories Limited or Xencor, Inc.: Who Manages SG&A Costs Better?
Jazz Pharmaceuticals plc vs Xencor, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.